australia - AusBiotech

28-29 October 2013
Melbourne Convention and Exhibition Centre
Victoria, Australia
AUSTRALIA
Co-organisers
Host State Sponsor
Benefit from expert analysis on the evolving landscape of biotech investment from:
Leading life science investors, analysts and advisors
Biotech companies presenting include
Dr Eric Shiozaki
Director
Apposite Capital
United States
Dr Jonathan
Wang
Senior Managing
Director
Orbimed Asia
China
Jeremy Curnock
Cook
Managing Director
Bioscience
Managers
Australia/United
Kingdom
Scott Power
Director of
Research
RBS Morgans
Australia
Dr Joshua Funder
Partner
GBS Venture
Partners
Australia
Lawrence Gozlan
CIO & Founder
Scientia Capital
Australia
David Blake
Editor
Bioshares Australia
John Granger
Founder
Hawkesbury
Partners
Australia
Dr Michael A.
Berry
Managing Director
Discovery
Investing
United States
Marc Sinatra
Equities Analyst
Lodge Partners
Australia
Dr Benjamin
Chen
Managing Partner
Ignatius
Transaction
Partners
United States
Dr Matthijs Smith
Senior Analyst
Canaccord
Genuity
Australia
Dr Chris Nave
Chief Executive
Officer
Medical Research
Commercialisation
Fund
Australia
Dr John Kurek
Investment
Manager
Uniseed Ventures
Australia
Dr Mel Billingsley
President and CEO
The Life Sciences
Greenhouse
of Central
Pennsylvania
United States
Stephen Nash
Co-Head, OTCQX
Markets Group
Cowen Group
United Sates
Dr Jason Mann
Managing Director
Fenex Capital
Management
Hong Kong
Kellee Kim
Research Analyst
EcoR1cap
United States
Ron Laufer
Senior Managing
Director
Medimmune
Ventures
United States
Dr Stewart
Washer
Chairman
iSonea
Australia
Global pharmaceutical companies
Augustine Yee
Asia Pacific Head
of Regional and
Corporate Business
Development and
China Vice President
of Business
Development
AstraZeneca
China
Dr James Garner
Head, Unit
Development
Office, Asia Pacific
R&D
Sanofi-Aventis
Singapore
Singapore
Dr Martin Judge
Director, Strategy
and Sourcing
Novo Nordisk A/S
Denmark
Dr Brian
Bloomquist
Senior Director,
Global External
Research and
Development
Eli Lilly
United States
Join Australia’s largest life science
deal-making event to:
Dr Brad Walsh
Minomic
International
Dr Cliff Holloway
Immune System
Therapeutics
Dr Deborah
Rathjen
Bionomics
Dr Geoff Cumming
Anteo Diagnostics
Dr Greg Collier
Invion
Howard Digby
EcoQuest
Dr John Holaday
QRxPharma
Dr Julian Chick
Allied Healthcare
Group
Julie Phillips
BioDiem
Dr Michelle
Miller
Biotron
Dr Paul MacLeman
IDT Australia
Enjoy exclusive access to our online
BioInvest Partnering tool:
• Learn about investment, partnering and capital raising strategies from an
international line-up of 40+ expert speakers
• Hear 30+ public and private biotech companies present their pipeline and
investment case
• Meet with 300+ senior level delegates from the Australian and international life
science community
Lanyard Sponsor
Dr Andrea Grant
Living Cell
Technologies
• Request and schedule one-on-one meetings with
other attendees
• Have direct access to the latest conference
agenda, floorplan, speaker bios and more
• View the profiles of all attendees
Silver Sponsors
Networking Sponsor
BERGEN
C
A
P
I
T
A
L
Supporting Associations
Supporting Organisations
Official PR Partner
To register, visit: www.AusBiotechInvest.com
call +852 2219 0111, email [email protected], or fax to +852 2219 0112
AUSTRALIA
28-29 October 2013
Melbourne Convention and Exhibition Centre
Australia’s premier biotech investment event
Contact us
Phone
Email
To be held in Melbourne, one of the great life science hubs in the world,+Australia
Biotech Invest will [email protected]
Australia’s biggest biotech
852 2219 0111
investment event to date. Building on AusBiotech’s successful Australasian Life Science Investment Summits, Australia Biotech
Beacon Events
Limitedthe
Invest extends to a two-day programme and will gather together hundreds
Australia
and across
Faxof life science investors fromMail:
20/F Siu On Centre, 188 Lockhart Road,
2219 0112
globe to discuss investment and partnership opportunities with a line-up+ 852
of cutting-edge
biotech companies.
Wanchai, Hong Kong
Brochure Code: BA699MM WEB
Conference Code: BA699
Combining high-value content with concrete investment
opportunities
In addition to biotech company presentations, the programme of Australia Biotech InvestVenue
2013 features
a mix of expert keynotes,
Information
investor and analyst panels and focus sessions to provide you with valuable marketMelbourne
intelligence
and act as your guide to biotech
Convention and Exhibition Centre
investment.
1 Convention Centre Place
I Strong
will attend::performance
South Wharf, Melbourne, Victoria 3006, Australia
Phone: (61 3) 9235 8000 Fax: (61 3) 9235 8001
for the biotech sector
This year is shaping up to be a good year for investment in the biotech sector. Globally, biotech stocks are surging, in the United
States
IPOs are being launched at the highest rate in more thanDays
10 years and overall strong performance
of the sector has placed
Conference
Thereafter
biotech back in the investor limelight. With a positive long-term outlook, now is an excellent time to learn more about how to gain
exposure to this exciting sector.
Conference only (28-29 October, 2013)
Sponsorship and Exhibiting Opportunities:
All prices in Australian Dollars (AUD) are inclusive of GST
Biotech companies come and present your pipeline to
2
Who Should Attend?
AU$ 2,744.50
•Institutional investors
On-site
AU$200
surcharge will
collected and no
discounts
available. Group discounts are available for three or more bookings from one company, please contact the organiser for more information.
theregistration:
assembled
audience
ofbeinvestors
and
big are
pharma
•Private equity investors
All discounts
can only be applied
at the
time offunds
registration
cannot be combined.
representatives
and
raise
orand
setdiscounts
up partnerships
toIn the event that more than one discount is applicable, delegates will receive the discount with the highest value. All
discounts are subject to approval. Please note the conference fee does not include travel or hotel accommodation costs.
•Venture capitalists
•Angel investors
Your Details (Please use BLOCK LETTERS)
Benefits for presenting biotech companies:
(Mr/Mrs/Ms/Miss/Dr) First Name
Last Name •Family offices
•Gain access to senior professionals representing investable
Job Title
Department
•Fund managers
capital globally
Direct
Tel
(
)
Mobile
(
)
•Pitch your investment case in an 8-minute spotlight
•Major pharmaceutical companies
Email presentation on the main conference stage to the
Direct Fax (
)
•Investment banks
assembled
Yes,
I would like audience
to receive information on future events via email. By giving you my email address. I am giving only the organisers the permission to contact me by email.
•Brokerage firms
•Enjoy exposure on the targeted marketing campaign
Approving
Manager
reaching
out to our extensive investor database and to •Stock exchanges
(Mr/Mrs/Ms/Miss/Dr)
Name
key businessFirst
development
professionals in pharma and Last Name
•Consultants
Job Title
Department
big biotech
•Analysts
•Explain further details of your research at your dedicated
Your Company Details
table top space at the exhibition
•Law firms
Company
•Set Name
up one-to-one meetings to discuss deals in private
•CMOs and CROs
Business
Nature
•Meet
with all the key stakeholders under one roof and No. of Employees
Address
enjoy excellent networking opportunities throughout Plus: Biotech companies looking for funding or partners
City the conference
State
Postcode
Country
drive your research forward.
Credit Card (All Card will be charged in HK$)
Payment Options:
Biotech companies confirmed to present so far include:
Please tick the relevant box to indicate your method of payment. Payment made in US$
(** When making payment, please include delegate name and conference code: BA699**)
Please tick the relevant box to indicate method of payment
Please send me an invoice.
(Payment instructions can be found on the invoice)
Payment will be made by bank transfer
Card Type:
Card No.
Cardholder’s Name
Cardholder’s Signature
Payment will be made by cheque or bank draft
BREAKTHROUGH PEPTIDE THERAPEUTICS
Expiry Date (mm/yy)
For enquiries, please contact:
Security Code (CVV2):
Payment Amount (US$)
Australia / New Zealand
Asia / Rest of the WorldDate:
Asia / Rest of the World
Speaking
&
Sponsorship
enquiries
Speaking
enquiries
Sponsorship enquiries
Cancellation Policy: Should you be unable to attend, a substitute delegate is always welcome at no extra charge. Alternatively, Beacon can also provide a credit note for attendance at any future events for cancellations received 14 days prior
Hayley
Laing a 50% refund will be provided for cancellations received inLot
Jongh
King
Tai
to
the event. Alternatively,
writingde
(letter
or facsimile) no later than four weeks prior to the event; thereafter
we regret
no refunds can be made. Beacon Events reserves the right to alter
the programme without notice including the substitution, alternation or cancellation of speakers and / or topics and / or alternation of the dates and / or location of the event. Beacon Events is not responsible for any loss or damage as a result of
T:
+613
9828
1400
T:
+852
2531
6140
T:
+852
2531 6125
a substitution, alternation, postponement or cancellation of any event. © 2013 Beacon Events Ltd. All rights reserved.
E: [email protected]
E: [email protected]
E: [email protected]
www.AsiaBiotechInvest.com
To register,
visit: www.AusBiotechInvest.com
To register,
contact
Beacon
at +852 2219 0111 [email protected]
call
+852 2219
0111,
emailEvents
[email protected],
fax to +852 2219 0112
AUSTRALIA
28-29 October 2013
Melbourne Convention and Exhibition Centre
08:30 Registration and morning coffee
09:00 WELCOME & OFFICIAL OPENING
The Honourable Gordon Rich-Phillips MLC, Minister for Technology,
STATE GOVERNMENT OF VICTORIA
Glenn Cross, Chief Operating Officer, AusBiotech
09:10 Conference chairman’s opening remarks and business card exchange
David Blake, Editor, Bioshares
GLOBAL STATE OF BIOTECH INVESTMENT
Contact us
VALUATION & RISK ASSESSMENT
Phone
Email
14:00+ 852
Valuing
opportunities [email protected]
optimising risk-return ratios
2219 biotech
0111
• Identifying investment opportunities and risk-return prospects across
Mail:of
Beacon
Events
Limited
a biotech
company
Fax the development and patent lifecycle
20/F
Siu patents,
On Centre,
188 Lockharttrack
Road,
• Putting
a price on biotech: How to
value
management
+ 852
2219 0112
Wanchai,
Hong
Kong
records and expected future revenue
/ royalty
streams
Brochure Code:
key factorsWEB
to keep in mind when investing into life science
• Ten BA699MM
companies
Conference Code:
BA699
• Small, mid or large-cap? De-risking your portfolio by diversifying your
biotech holdingVenue Information
• UtilisingMelbourne
the discovery
investment
scoreboard
technology to pick the
Convention
and Exhibition
Centre
best stocks
1 Convention Centre Place
Dr Michael
A. Berry,
Discovery
South
Wharf, Managing
Melbourne,Director,
Victoria 3006,
AustraliaInvesting
keynote
Conference Day One
28 October 2013
Phone: (61 3) 9235 8000 Fax: (61 3) 9235 8001
PARTNERING STRATEGIES
• Analysing investment and business trends driving biotechnology today
14:20 PHARMA PANEL: Strategic partnering for long-term success
• Demographic, macro-economic and policy developments impacting • Examining successful partnership
models: How to achieve a Conference
Days
Thereafter
the sector
win-win partnership
• Exploring innovative investment strategies to benefit from emerging
• Commercialising innovation: Impact of strategic alliances and JVs on
opportunities in biotech
cost / revenue models and success rate of drug development
DrConference
Eric Shiozaki,
Apposite Capital
2
only Director,
(28-29 October,
2013)
• Partnerships key challengesAU$
and2,744.50
opportunities
Moderator:
Glenn
Cross,
Chief
Operating Officer, AUSBIOTECH
09:35 Exploring biotech’s evolving investment landscape – challenges and
Panellists:
All prices inopportunities
Australian Dollars (AUD) are inclusive of GST
Augustine Yee, Asia Pacific Head of Regional and Corporate Business
• Long-term investment outlook for biotech from the investors’
On-site registration: AU$200 surcharge will be collected and no discounts are available. Group discounts are available for
three or more bookings
from Vice
one company,
please
the organiser
for more information.
Development
and China
President
of contact
Business
Development,
perspective
All discounts can only be applied at the time of registration and discounts cannot be combined. In the event that more than one
discount is applicable, delegates will receive the discount with the highest value. All
AstraZeneca
• What’s hot in life sciences and where is the smart money being
discounts are subject to approval. Please note the conference fee does not include travel or hotel accommodation costs. Dr Martin Judge, Director, Strategy and Sourcing, Novo Nordisk A/S
invested?
Dr Brian Bloomquist, Senior Director, Global External Research and
• Ways to gain exposure to the biotech boom: Stocks, funds, private
Development, Eli Lilly
Your Details
(Please
use BLOCK
equity,
venture
capitalLETTERS)
or else? Expert investor’ views on the best
Dr Raman Rao, Head External R&D, Asia Pacific, SANOFI PASTEUR
vehicles for
biotech
(Mr/Mrs/Ms/Miss/Dr)
First
Name investment
Last Name
• Funding the future of biotech: Key challenges and opportunities
Job Title
Department15:00 Biotech Company Spotlight Presentations
Moderator: David Blake, Editor, Bioshares
Carl Stubbing, Chief Business Officer, Benitec Biopharma (ASX:BLT)
Direct TelPanellists:
(
)
Mobile (
)
Dr Julian Chick, COO, Allied Healthcare Group (ASX:AHG)
Dr Jonathan Wang, Senior Managing Director, Orbimed Asia
Email
Direct Fax (
)
Dr Andrea Grant, CEO, Living Cell Technologies (ASX:LCT)
Jeremy Curnock Cook, Managing Director, Bioscience Managers
MarkI am
Diamond,
Managing
Directorthe
& CEO,
Directorinformation
of Research,
RBS Morgans
Yes, IScott
wouldPower,
like to receive
on future
events via email. By giving you my email address.
giving only
the organisers
permission
to contact me by email.
ANTISENSE THERAPEUTICS (ASX:ANP)
Dr Joshua Funder, Partner, GBS Venture Partners
Approving Manager
10:15 Biotech Company Spotlight Presentations
15:35 Afternoon tea and networking with exhibitors
(Mr/Mrs/Ms/Miss/Dr) First Name
Last Name
Julie Phillips, CEO, BioDiem (ASX:BDM)
R&D and TAX INCENTIVES
Job Title Dr John Holaday, Managing Director, CEO and CSO, QRxPharma Department
(ASX:QRX)
16:00 Maximising your after tax return on investment in Australia –
Your Company
Details
Dr Brad Walsh,
CEO, Minomic International
strategies and opportunities
Greg Collier, CEO, Invion (ASX:IVX)
CompanyDr
Name
• Tax and financial structures for start-ups in order to leverage the R&D
Dr
Ross
Macdonald,
CEO
and
Managing
Director,
ECOQUEST
(ASX:ECQ)
Business Nature
No. of Employees
incentive and maximise Return on Investment
Address
11:00 Morning refreshments and networking with exhibitors
• Current “state of play” of the R&D tax incentives and grants available
• Biotech start-up taxCcase
– tips and traps for first time and
City
State
Postcode
ountstudy
ry
11:30 The changing face of biotech investment
experienced applicants, including tax and R&D considerations
the
current
state
of
venture
capital
and
private
equity
•
Assessing
Payment Options:
Credit•Card
(All Card
will be charged inIncentive
HK$)
Australian
Manufacturing
investment into biotech
Helen Fisher, Corporate & International Tax Partner, Deloitte
Please tick the
relevant
box
to
indicate
your
method
of
payment.
Payment
made
in
US$
• Examining the role of institutional investors in the biotech space
Sergio Duchini, R&D & Government Incentives Partner, Deloitte
Card Type:
(** When making
payment, please
nameinand
conference code: BA699**)
• Attracting
superinclude
fundsdelegate
to invest
biotech
• Managing risk at all stages: Exploring risk mitigation strategies for
ANALYSTS’ VIEW
biotech investors
Card No.
Please •tick
the
relevant
box
to
indicate
method
of
payment
Lessons learned from investing in biotech
16:45 ANALYST ROUNDTABLE: Analysing the biotech boom
Moderator: David Blake, Editor, Bioshares
• Biotech drivers and performance in Australia and New Zealand
Please
send
me
an
invoice.
Panellists:
Cardholder’s
Name
• What
stocks are on the analysts’ watchlist and why?
(Payment
instructions
be Investment
found on theOfficer
invoice)
Lawrence
Gozlan,can
Chief
and Founder, Moderator: David Blake, Editor, Bioshares
Scientia Capital
Panellists:
Payment will be made by bank transfer
Cardholder’s
Signature
Michael Glenane, Executive Director, Fairview Equity Partners
Marc Sinatra, Equities Analyst, Lodge Partners
John
Granger,
Partners
Payment
will beFounder,
made byHawkesbury
cheque or bank
draft
Dr Graeme Wald, Investment Director, Bioscience Managers
Graeme Colley, Director of Technical and Professional Standards, SELF
Scott Power, Director of Research, RBS Morgans
MANAGED SUPER FUNDS PROFESSIONALS ASSOCIATION OF AUSTRALIA
Matthijs
ExpiryDr
Date
(mm/yy) Smith, Senior Analyst,
Security CANACCORD
Code (CVV2): GENUITY
Graydon Smith, Manager Venture Capital Fund, R&D, AUSINDUSTRY
PANEL
PANEL
PANEL
PANEL
keynote
Global biotech investment trends and opportunities
I09:15
will attend::
17:30
Networking Reception
Sponsored by
Payment
Amount (US$)
12:10 Biotech Company Spotlight Presentations
Dr Deborah Rathjen, CEO, Bionomics (ASX:BNO)
Date:
Dr Paul MacLeman, CEO, IDT Australia (ASX:IDT)
Dr Michelle Miller, CEO, Biotron (ASX:BIT)
Cancellation
Policy:Walker,
Should you CEO,
be unable
to attend, a substitute
delegate is always welcome at no extra charge. Alternatively, Beacon can also provide a credit note for attendance at any future events for cancellations received 14 days prior
Charles
ALCHEMIA
(ASX:ACL)
to the event.
Alternatively,
a 50% refund
will be provided
for cancellations
received
in writing
(letter or facsimile) no later than four weeks prior to the event; thereafter we regret no refunds can be made. Beacon Events reserves the right to alter
Stephen
Carter,
Executive
Chairman
and CEO,
SUDA
(ASX:SUD)
the programme
without
noticeCEO,
including
the substitution, alternation or cancellation of speakers and / or topics and / or alternation of the dates and / or location of the event. Beacon Events is not responsible for any loss or damage as a result of
Robert
Mair,
FITGENES
a substitution, alternation, postponement or cancellation of any event. © 2013 Beacon Events Ltd. All rights reserved.
13:00 Lunch and networking with exhibitors
www.AsiaBiotechInvest.com
To register,
visit: www.AusBiotechInvest.com
To register,
contact
Beacon
at +852 2219 0111 [email protected]
call
+852 2219
0111,
emailEvents
[email protected],
fax to +852 2219 0112
AUSTRALIA
28-29 October 2013
Melbourne Convention and Exhibition Centre
08:30 Registration and morning coffee
09:00 Conference chairman’s opening remarks and day one recap
Dr Fintan Walton, Founder and CEO, PharmaVentures
Contact us
Phone
ASIA AND CHINA FOCUS SESSION
Email
14:00+ 852
Asia’s
growing
and investment
2219
0111 role in biotech innovation
[email protected]
• Examining Asia’s biotech landscape and key drivers for future growth
into
and out
of Asia
Mail: Beacon
Events
Limited
Fax• Flows of biotech innovation and investment
Siu On Centre, 188
Lockhart Road,
• Market
outlook and opportunities20/F
for Australian-Asian
partnerships
+ 852
2219 0112
Hong Kong
Dr Jason Mann, Managing Director, Wanchai,
FENEX CAPITAL
MANAGEMENT
keynote
Conference Day Two
29 October 2013
Brochure Code: BA699MM WEB
14:20 How to access investment out of China?
in China look for when investing into biotech
companies? What types of companies at what stage are most
Venue
Information
09:10 Biotech financing and business models for future growth
favoured?
• Key success factors and business models to monetise innovation
Melbourne
Convention
and
Exhibitionbest
Centre
• Pitch perfect: How can biotech
companies
position themselves
• Access to finance: Capital raising for early and late-stage biotechs
to attract capital1and/or
set up
partnerships
in China?
Convention
Centre
Place
• Investment exit strategies anno 2013
• Exploring
biotech
raising
success
and successful
South
Wharf,capital
Melbourne,
Victoria
3006,stories
Australia
Kellee Kim, Research Analyst, ECOR1CAP
investor
exits(61 3) 9235 8000 Fax: (61 3) 9235 8001
Phone:
I will attend::
• Accessing grants and funding and collaborating across borders
09:30 BIOTECH BROKERS PANEL: Outlook for life science stocks
Moderator: Dr Fintan Walton, Founder and CEO, PharmaVentures
• Assessing the performance of life science stocks across key exchanges
Panellists:
• Spotlight on recent listings and upcoming IPOs
Rob Scott, Director, China Bluesky
Ventures
Conference
Thereafter
• Small-cap, mid-cap, large-cap: Where are the best opportunities? Days
Dr Benjamin Chen, Managing Partner, Ignatius Transaction Partners
Moderator: Dr Fintan Walton, Founder and CEO, PharmaVentures
Dr Jason Mann, Managing Director, FENEX CAPITAL MANAGEMENT
Panellists:
Joanna
Hill, Client
Services
Manager,
EL & C Baillieu Stockbroking 2 15:00 Biotech Company Spotlight AU$
2,744.50
Conference
only (28-29
October,
2013)
Presentations
Steven Yatomi-Clarke, Director Corporate Finance, Mark Heffernan, Chief Executive Officer, NEXVET BIOPHARMA
Patersons Securities
All prices inSam
Australian
Dollars
(AUD) are Director
inclusive ofCorporate
GST
Associate
Finance, RBS Morgans
Street,
Nick Ede, Executive Director, Imugene (ASX:IMU)
James Posnett, Manager, Listing Business Development, ASX
Drthree
Clement
ASCEND
BIOPHARMACEUTICALS
On-site registration: AU$200 surcharge will be collected and no discounts are available. Group discounts are available for
or moreLeong,
bookings CEO,
from one
company,
please contact the organiser for more information.
All discounts can only be applied at the time of registration and discounts cannot be combined. In the event that more than one
discountJohnson,
is applicable,CEO,
delegates
will receive(ASX:CGP)
the discount with the highest value. All
Michael
RHINOMED
10:10 Biotech Company Spotlight Presentations
Conference
•Code:
What BA699
do investors
PANEL
PANEL
keynote
BIOTECH PERFORMANCE AND GROWTH OUTLOOK
discounts are subject to approval. Please note the conference fee does not include travel or hotel accommodation costs.
Geoffrey Kempler, Executive Chairman, PRANA BIOTECHNOLOGY
15:40
(ASX:PBT)
Your Details (Please use BLOCK LETTERS)
Dr Tom McCarthy, CEO & Managing Director, SPINIFEX PHARMACEUTICALS
(Mr/Mrs/Ms/Miss/Dr)
First Name
Last Name
Roger McPherson,
CFO, PATRYS (ASX:PAB)
Job Title Dr Geoff Cumming, CEO, ANTEO DIAGNOSTICS (ASX:ADO)
Department16:00
Dr Cliff Holloway, CEO, IMMUNE SYSTEM THERAPEUTICS
Direct TelSerina
(
)Cucuzza, Manager Commercial Development and Industry Mobile (
)
Engagement,
BURNET
INSTITUTE
Email
Direct Fax (
Afternoon tea and networking with exhibitors
THE FUTURE OF BIOTECH INVESTMENT
PANEL
PANEL
Creating value from spin-offs
• Role of universities, incubators and research institutes in driving
biotech innovation
) • Accessing funding for university research and spin-offs
• Bridging the gap: How best to put research to commercial use
Yes, IMorning
would like
to receive information
on future
events
via email. By giving you my email address. I am giving only the organisers the permission to contact me by email.
11:00
refreshments
and networking
with
exhibitors
• How to create investor value from spin-offs: Success stories and
lessons learned
Approving
Manager
11:30 Spotlight on Victoria’s biotechnology industry capabilities
Moderator: Dr Fintan Walton, Founder and CEO, PharmaVentures
Government
Representative,
(Mr/Mrs/Ms/Miss/Dr)
FirstVictorian
Name
Last Name
Panellists:
Dr Chris Nave, Chief Executive Officer, Medical Research
Job Title
Department
PROTECTING YOUR IP RIGHTS
Commercialisation Fund
Dr John Kurek, Investment Manager, Uniseed Ventures
Your
Details for capital raising and investment
12:00Company
IP Due Diligence
Dr Mel Billingsley, President and CEO, The Life Sciences Potential threats to a biotech company’s IP rights
Company•Name
Greenhouse of Central Pennsylvania
• Getting your IP house in order prior to raising capital
Business Nature
No. of Employees Ron Laufer, Senior Managing Director, MEDIMMUNE VENTURES
• Security around IP that investors should seek when investing Address
into biotech
16:30 Biotech Company Spotlight Presentations
City
State
Postcode
Coun
try
Dr Richard Hopkins, CEO,
PHYLOGICA
(ASX: PYC)
12:20 Biotech Company Spotlight Presentations
Paul Wright, Chief Executive Officer, UNIVERSAL BIOSENSORS (ASX:UBI)
Payment
Options:
Credit Card (All Card will be charged in HK$)
Simon
Wilkinson, Director & CEO, INNATE IMMUNOTHERAPEUTICS
16:55 Key challenges and investment opportunities for biotech in coming
Please tick the
relevant
box toChairman
indicate your&method
of payment.(ASX:
Payment
made in US$
Nick
Weston,
CEO, AGENIX
AGX)
10 years
Card Type:
(** When making
please
delegate
name and conference code: BA699**)
Mikepayment,
Thomas,
CEO,include
ISONEA
(ASX:ISN)
• Key challenges and opportunities for biotech investment and
Uwe Schlokat, CEO, SENTINEXT THERAPEUTICS
innovation going forward
Card No.
• Who will be funding early stage biotech to keep the momentum
Please tick the relevant box to indicate method of payment
13:00 Lunch and networking with exhibitors
going?
Please send me an invoice.
• Key trends in the healthcare space and how these may affect biotech
Cardholder’s
Name
innovation
and investment in the years to come
(Payment instructions can be found on the invoice)
• Will biotech live up to its potential?
Payment will be made by bank transfer
Cardholder’s
Signature
Moderator:
Dr Fintan Walton, Founder and CEO, PharmaVentures
Panellists:
Payment will be made by cheque or bank draft
Glenn Cross, Chief Operating Officer, AusBiotech
Kellee Kim, Research Analyst, ECOR1CAP
ExpiryEric
DateShiozaki,
(mm/yy)
SecurityCAPITAL
Code (CVV2):
Director, APPOSITE
Rhenu Bhuller, Global Vice President Pharmaceuticals/Biotechnology,
FROST
& SULLIVAN
Payment
Amount
(US$)
Dr Stewart Washer, Chairman, ISONEA
Date: Dr James Garner, Head, Unit Development Office, Asia Pacific R&D,
SANOFI-AVENTIS SINGAPORE
Cancellation Policy: Should you be unable to attend, a substitute delegate is always welcome at no extra charge. Alternatively, Beacon can also provide a credit note for attendance at any future events for cancellations received 14 days prior
17:30 Chairman’s closing remarks and end of conference
to the event. Alternatively, a 50% refund will be provided for cancellations received in writing (letter or facsimile) no later than four weeks prior to the event; thereafter we regret no refunds can be made. Beacon Events reserves the right to alter
the programme without notice including the substitution, alternation or cancellation of speakers and / or topics and / or alternation of the dates and / or location of the event. Beacon Events is not responsible for any loss or damage as a result of
a substitution, alternation, postponement or cancellation of any event. © 2013 Beacon Events Ltd. All rights reserved.
www.AsiaBiotechInvest.com
To register,
visit: www.AusBiotechInvest.com
To register,
contact
Beacon
at +852 2219 0111 [email protected]
call
+852 2219
0111,
emailEvents
[email protected],
fax to +852 2219 0112
AUSTRALIA
28-29 October 2013
Melbourne Convention and Exhibition Centre
Profiles of previous delegates to Asia
Biotech Invest 2013:
Contact
Investors attending
AsiausBiotech Invest
Phone
Email
2013
included:
+ 852 2219 0111
[email protected]
8T8 Capital • AK Partners HK • AP Capital Group • Asia
Mail: Beacon Events Limited
Fax
Pacific
Investment Advisors • 20/F
Avenue
Capital
GroupRoad,
•
Siu On Centre,
188 Lockhart
+ 852 2219 0112
Academic /
Wanchai,
Hong Kong
Stock Exchange
Ballingal
Investment
Advisors
•
Baring
Private
Equity
Association
1%
Brochure Code: BA699MM WEB
Partners Asia • Baron Group - Baron Capital • Bioscience
Communications 6%
Science Park
Conference Code: BA699
1%
Managers • BioVeda China Fund • BOCI-Prudential Asset
Research 1%
Government
Institute
4%
Venue Information
Biotech
Management • Business
Succession Partners • Caitong
Services
1%
13%
10%
Melbourne
Convention and Exhibition
Centre & Associates •
International
Asset
Management
• Capvest
Pharma
1 Convention Centre Place
8%
CCB International
Asset
Management
• Australia
Cedrus Investments
South Wharf,
Melbourne,
Victoria 3006,
Investor
Phone:
(61
3)
9235
8000
Fax:
(61
3)
9235
8001
HK
•
Celadon
Capital
Malaysia
•
Chepstow
Capital Advisors
47%
I will attend::
• China BlueSky Ventures • CMS Asset Management HK •
Creata Group • DAC Financial Management China • Decheng
Media
Conference
Days
Thereafter
8%
Capital • Deltec Capital • Discovery Investing • Ellis Brady
Management HK • Etoile Asset Management • Fortune Time
2 Capital Holding Group • Franklin
AU$ 2,744.50
Conference only (28-29 October, 2013)
Templeton Investments
JOB FUNCTION
Asia
•
Global
Mining
Capital
Corporation
• Gottex Penjing
Analyst
All prices in Australian Dollars (AUD) are inclusive of GST
Asset Management • Green Mountains Investments •
2%
BD/Marketing
On-site registration: AU$200 surcharge will be collected and no discounts are available. Group discounts are available for three or more bookings from one company, please contact the organiser for more information.
C-Level
12%
Greenwoods
Management
International
All discounts can only be applied at the time of registration and discounts cannot be combined. In the event that more
than one discountAsset
is applicable,
delegates will receive•theGuangdong
discount with the highest
value. All
16%
discounts are subject to approval. Please note the conference fee does not include
travel or hotel accommodationCapital
costs.
Consultant
•
GYK
Holdings
•
Harmony
Asset
Management
•
36%
Investment
4%
Hong
Kong
Institute
of
Biotechnology
•
Infinity
Group
•
Your Details (Please use BLOCK LETTERS)
Media
18%
JAG
Investments
•
JPMorgan
Asset
Management
Real
Assets
(Mr/Mrs/Ms/Miss/Dr) First Name
Last Name
4%
Others
Job Title
Regulatory DepartmentAsia • Kaiwu Capital • Khazanah Nasional Berhad • Leon
Capital Management Hong Kong • LGT Capital Partners
Direct Tel (
)
Mobile ( CVM
)
Research
Asia
3%
Senior
Email
Direct Fax (
)Pacific • Lilly Asia Ventures • Lim Global Investment
3% 2%
Management
& Research
Liomer
Holdings
H Carnegie
& me
Coby• email.
Muse
Yes, I would like to receive information on future events via email. By giving you my email
address. I am•giving
only the
organisers •
theM
permission
to contact
Capital
•
Nan
Fung
Group
•
Optivest
Capital
•
OrbiMed
Asia
Approving Manager
INVESTORS - JOB FUNCTION
(Mr/Mrs/Ms/Miss/Dr) First Name
Last Name• Pacific West Asia Asset Management • PharmaVentures •
Job Title
DepartmentPrimavera Capital • Qiming Ventures • Quadria Capital •
Analyst
Qualita • Quam • RimAsia Capital Partners • Rock Spring
5%
Others
Your Company Details
Ventures • RRJ Management HK • Saba Capital • Sequoia
20%
Company Name
Capital
• Shaw Kwei & Partners • Sinovest Capital • STIC
Business Nature
No. of Employees
C-Level /
Investment
• Stratagem Capital • Sumitomo Mitsui Asset
Senior
Management
Address
75%
Bank
City
State
Postcode Management HK • TheCo
untry of East Asia • The Longreach
Group
•
Tian
An
China
Investments
• Tripod Capital • Valiant
Payment Options:
Credit Card (All Card will be charged in HK$)
Ocean
Investment
•
Ventac
Partners
HK • Vivo Ventures •
Please tick the relevant box to indicate your method of payment. Payment made in US$
Card
Type:
(** When making payment, please include delegate name and conference code: BA699**)
Wellcome Trust • Yuuwa Capital
COMPANY TYPE
Card No.
Please
boxAsia
to indicate
“Fromtick
its the
firstrelevant
edition,
Biotechmethod
Investofispayment
already the ‘must-go’ event for both biotech investors and fund-seekers in Asia”
Please send me an invoice.
(Payment instructions can be found on the invoice)
Andrew Badrot, CMS Advisors
Cardholder’s Name
“As the world becomes increasingly Asia-centric, it is essential that our company develops links and contacts in the Biotech and
Payment
will be made by
Cardholder’s Signature
Investment
communities
inbank
Asia.transfer
The work of AusBiotech in proactively assisting
in this through the Asia Biotech Invest summit enabled
us to Payment
link in effectively
quickly.
We’lldraft
be back.”
Sean Parsons, Ellume
will be madeand
by cheque
or bank
“We were very pleasantly surprised by the number and calibre of the investors
that attended theSecurity
meeting.
We had a number of very
Expiry Date (mm/yy)
Code (CVV2):
productive meetings and are pursuing two strong leads in our capital raising efforts directly as a result of the Asia Biotech Invest
Payment Amount (US$)
meeting.”
Dr Brad Walsh, Minomic International
Media Partners
Date:
Cancellation Policy: Should you be unable to attend, a substitute delegate is always welcome at no extra charge. Alternatively, Beacon can also provide a credit note for attendance at any future events for cancellations received 14 days prior
to the event. Alternatively, a 50% refund will be provided for cancellations received in writing (letter or facsimile) no later than four weeks prior to the event; thereafter we regret no refunds can be made. Beacon Events reserves the right to alter
the programme without notice including the substitution, alternation or cancellation of speakers and / or topics and / or alternation of the dates and / or location of the event. Beacon Events is not responsible for any loss or damage as a result of
a substitution, alternation, postponement or cancellation of any event. © 2013 Beacon Events Ltd. All rights reserved.
www.AsiaBiotechInvest.com
To register,
visit: www.AusBiotechInvest.com
To register,
contact
Beacon
at +852 2219 0111 [email protected]
call
+852 2219
0111,
emailEvents
[email protected],
fax to +852 2219 0112
AUSTRALIA
May 2013
2013
28-2914-15
October
Renaissance
Harbourand
View
Hotel, Hong Kong
Melbourne
Convention
Exhibition
Centre
Contact us
Phone
+ 852 2219 0111
Email
[email protected]
Fax
+ 852 2219 0112
Mail: Beacon Events Limited
20/F Siu On Centre, 188 Lockhart Road,
Wanchai, Hong Kong
Brochure Code: BA699MM WEB
Conference Code: BA699
Venue Information
Melbourne Convention and Exhibition Centre
1 Convention Centre Place
South Wharf, Melbourne, Victoria 3006, Australia
Phone: (61 3) 9235 8000 Fax: (61 3) 9235 8001
I will attend::
Conference
Conference only (28-29 October, 2013)
Days
Thereafter
2
AU$ 2,744.50
All prices in Australian Dollars (AUD) are inclusive of GST
On-site registration: AU$200 surcharge will be collected and no discounts are available. Group discounts are available for three or more bookings from one company, please contact the organiser for more information.
All discounts can only be applied at the time of registration and discounts cannot be combined. In the event that more than one discount is applicable, delegates will receive the discount with the highest value. All
discounts are subject to approval. Please note the conference fee does not include travel or hotel accommodation costs.
Your Details
(Please use BLOCK LETTERS)
(Mr/Mrs/Ms/Miss/Dr) First Name
Last Name
Job Title
Department
Direct Tel (
)
Mobile (
Email
Direct Fax (
)
)
Yes, I would like to receive information on future events via email. By giving you my email address. I am giving only the organisers the permission to contact me by email.
Approving Manager
(Mr/Mrs/Ms/Miss/Dr) First Name
Last Name
Job Title
Department
Your Company Details
Company Name
Business Nature
No. of Employees
Address
City
State
Payment Options:
Please tick the relevant box to indicate your method of payment. Payment made in US$
(** When making payment, please include delegate name and conference code: BA699**)
Please tick the relevant box to indicate method of payment
Please send me an invoice.
(Payment instructions can be found on the invoice)
Payment will be made by bank transfer
Postcode
Country
Credit Card (All Card will be charged in HK$)
Card Type:
Card No.
Cardholder’s Name
Cardholder’s Signature
Payment will be made by cheque or bank draft
Expiry Date (mm/yy)
Security Code (CVV2):
Payment Amount (US$)
Date:
Cancellation Policy: Should you be unable to attend, a substitute delegate is always welcome at no extra charge. Alternatively, Beacon can also provide a credit note for attendance at any future events for cancellations received 14 days prior
to the event. Alternatively, a 50% refund will be provided for cancellations received in writing (letter or facsimile) no later than four weeks prior to the event; thereafter we regret no refunds can be made. Beacon Events reserves the right to alter
the programme without notice including the substitution, alternation or cancellation of speakers and / or topics and / or alternation of the dates and / or location of the event. Beacon Events is not responsible for any loss or damage as a result of
a substitution, alternation, postponement or cancellation of any event. © 2013 Beacon Events Ltd. All rights reserved.
www.AsiaBiotechInvest.com
To register,
visit: www.AusBiotechInvest.com
To register,
contact
Beacon
at +852 2219 0111 [email protected]
call
+852 2219
0111,
emailEvents
[email protected],
fax to +852 2219 0112